NASDAQ: MIRMMirum Pharmaceuticals Inc Stock
$24.49+0.47 (+1.96%)
Updated Apr 25, 2024
MIRM Price
$24.49
Fair Value Price
N/A
Market Cap
$1.15B
52 Week Low
$23.14
52 Week High
$35.56
P/E
-6.12x
P/B
4.63x
P/S
6.48x
PEG
N/A
Dividend Yield
N/A
Revenue
$186.37M
Earnings
-$163.42M
Gross Margin
74.8%
Operating Margin
-79.04%
Profit Margin
-87.7%
Debt to Equity
1.6
Operating Cash Flow
-$71M
Beta
0.98
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MIRM Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MIRM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIRM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MIRM is good value based on its book value relative to its share price (4.63x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
MIRM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MIRM due diligence checks available for Premium users.
Be the first to know about important MIRM news, forecast changes, insider trades & much more!
MIRM News
Valuation
MIRM fair value
Fair Value of MIRM stock based on Discounted Cash Flow (DCF)
Price
$24.49
Fair Value
$0.79
Overvalued by
3,005.98%
MIRM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MIRM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.12x
Industry
15.41x
Market
40.97x
MIRM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.63x
Industry
5.8x
MIRM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIRM's financial health
Profit margin
Revenue
$69.6M
Net Income
-$35.7M
Profit Margin
-51.3%
MIRM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MIRM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$646.6M
Liabilities
$398.0M
Debt to equity
1.6
MIRM's short-term assets ($387.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIRM's short-term assets ($387.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIRM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MIRM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.6M
Investing
-$2.0M
Financing
$1.8M
MIRM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MIRM vs Biotech Stocks
Mirum Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.